Filing summary
Entity and period: The supplied filing is Zafgen, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017, filed May 9, 2017. It is not a Larimar Therapeutics filing; verify that this is the intended company and filing.
Business context and reporting period
Zafgen was a development-stage biopharmaceutical company focused on MetAP2 inhibitors for metabolic diseases. Its lead candidate was ZGN-1061, being developed for conditions including type 2 diabetes and obesity. The company had no product revenue and reported recurring operating losses.
During the quarter, Zafgen completed dosing in the Phase 1 single- and multiple-ascending-dose portions of the ZGN-1061 trial. The filing also reports that positive trial results were announced in May 2017, after the quarter-end.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.7 million | $12.5 million |
| General and administrative expense | $3.6 million | $5.4 million |
| Total operating expenses | $13.3 million | $17.9 million |
| Net loss | $13.0 million | $17.7 million |
| Net loss per share, basic and diluted | $0.48 | $0.65 |
| Cash used in operating activities | $11.7 million | $17.8 million |
At March 31, 2017, cash and cash equivalents were $28.6 million and marketable securities were $88.3 million, totaling approximately $116.9 million. Total assets were $119.4 million, total liabilities $8.6 million, and stockholders’ equity $110.8 million. Notes payable, reported as current, were $2.8 million; the outstanding facility carried an effective annual interest rate of approximately 10.8%.
No operating margin is meaningful because the company had no revenue. Management stated that available cash, cash equivalents and marketable securities were expected to fund planned operations and capital expenditures for at least one year from the report’s issuance date. This estimate depended on assumptions that could prove incorrect.
Material changes versus the prior comparable period
- Net loss narrowed by $4.7 million and operating expenses declined by $4.6 million year over year, primarily reflecting suspension of beloranib development and a reduced workforce.
- R&D expense fell $2.8 million overall, while ZGN-1061 program costs increased $4.1 million as Phase 1 work and preparation for later trials advanced.
- G&A expense declined $1.8 million, including lower stock-based compensation, professional fees and personnel costs.
- Operating cash use decreased by $6.1 million year over year. Cash and cash equivalents declined $3.7 million during Q1 2017.
- Cash, cash equivalents and marketable securities decreased from approximately $129.2 million at December 31, 2016 to $116.9 million at March 31, 2017.
Outlook, risks and unusual items
- Zafgen planned to start a Phase 2 ZGN-1061 trial in overweight or obese patients with type 2 diabetes in Australia and New Zealand in the second half of 2017. It expected R&D costs to rise as development progressed and G&A costs to decline during 2017 versus 2016.
- Key risks include dependence on ZGN-1061, clinical and regulatory uncertainty, and the possibility that the thrombotic safety concerns associated with prior candidate beloranib could affect development of MetAP2 inhibitors. Phase 1 results do not establish longer-term safety or efficacy.
- The company had no revenue and expected continuing losses. Future financing could be necessary; equity financing could dilute shareholders, while collaborations or licensing could require giving up valuable rights.
- The beloranib-related securities class action dismissal was affirmed on appeal on April 7, 2017. The filing reported no known material claims as of March 31.
- The company had restructured after suspending beloranib, reducing its workforce by approximately 31% by December 2016. An $80,000 restructuring reserve remained at quarter-end.
- Other disclosed exposures include foreign-exchange risk (the company did not hedge; a modeled 10% unfavorable currency move would have increased quarterly net loss by $0.2 million), pledged personal property under the credit facility, and potential beloranib license milestone payments.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing identifies Zafgen, Inc., not Larimar Therapeutics, Inc.
- Check subsequent regulatory, clinical and safety updates for ZGN-1061, including whether the planned Phase 2 trial began and its results.
- Monitor cash burn, financing needs and whether the stated minimum one-year runway remained valid as development costs changed.
- Review the company’s current debt obligations and the terms, timing and potential impact of any new financing or partnership.
- Assess whether the beloranib safety history, clinical-trial requirements, manufacturing dependencies and intellectual-property rights affect ZGN-1061’s prospects.